Minimal residual disease (MRD) detection using liquid biopsy is an emerging tool for risk stratification and monitoring for recurrence in resected early-stage NSCLC. There is increasing need for clear guidance on its optimal clinical implementation.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 26 Mar 2026.
The item focuses on Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC – A Delphi study by the Asian Thoracic Oncology Research Group (ATORG).
Review the original article for the full source wording and details.